JP2008545145A - 対応治療抗体の有無を問わない標的抗原の検出 - Google Patents

対応治療抗体の有無を問わない標的抗原の検出 Download PDF

Info

Publication number
JP2008545145A
JP2008545145A JP2008519853A JP2008519853A JP2008545145A JP 2008545145 A JP2008545145 A JP 2008545145A JP 2008519853 A JP2008519853 A JP 2008519853A JP 2008519853 A JP2008519853 A JP 2008519853A JP 2008545145 A JP2008545145 A JP 2008545145A
Authority
JP
Japan
Prior art keywords
antibody
therapeutic antibody
target antigen
sample
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008519853A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008545145A5 (enExample
Inventor
レンツ，ヘルムート
ショイアー，ベルナー
ティアー，マルティナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2008545145A publication Critical patent/JP2008545145A/ja
Publication of JP2008545145A5 publication Critical patent/JP2008545145A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2008519853A 2005-07-06 2006-07-05 対応治療抗体の有無を問わない標的抗原の検出 Pending JP2008545145A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05014618 2005-07-06
EP06004447 2006-03-06
PCT/EP2006/006524 WO2007003420A1 (en) 2005-07-06 2006-07-05 Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody

Publications (2)

Publication Number Publication Date
JP2008545145A true JP2008545145A (ja) 2008-12-11
JP2008545145A5 JP2008545145A5 (enExample) 2010-11-18

Family

ID=36922121

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008519853A Pending JP2008545145A (ja) 2005-07-06 2006-07-05 対応治療抗体の有無を問わない標的抗原の検出

Country Status (19)

Country Link
US (1) US20070009976A1 (enExample)
EP (2) EP2194380A3 (enExample)
JP (1) JP2008545145A (enExample)
KR (1) KR20080016939A (enExample)
AR (1) AR053948A1 (enExample)
AU (1) AU2006265275A1 (enExample)
BR (1) BRPI0612591A2 (enExample)
CA (1) CA2613187A1 (enExample)
CR (1) CR9635A (enExample)
EC (1) ECSP088081A (enExample)
IL (1) IL188317A0 (enExample)
MA (1) MA29730B1 (enExample)
MX (1) MX2008000277A (enExample)
MY (1) MY157955A (enExample)
NO (1) NO20076662L (enExample)
NZ (1) NZ564471A (enExample)
RU (1) RU2008103608A (enExample)
TW (1) TWI312864B (enExample)
WO (1) WO2007003420A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ522444A (en) * 2000-05-19 2004-09-24 Genentech Inc Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy
SI1771482T1 (sl) * 2004-07-22 2014-12-31 Genentech, Inc. Sestavek HER2 protitelesa
WO2007092545A2 (en) 2006-02-07 2007-08-16 The Board Of Trustees Of The Leland Stanford Junior University Variable imaging arrangements and methods therefor
KR101134208B1 (ko) 2004-10-01 2012-04-09 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 촬상 장치 및 그 방법
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
NZ590431A (en) 2005-02-23 2012-08-31 Genentech Inc Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US8358354B2 (en) 2009-01-26 2013-01-22 The Board Of Trustees Of The Leland Stanford Junior University Correction of optical abberations
CN101680897B (zh) 2007-03-02 2013-11-13 健泰科生物技术公司 基于低her3表达预测对her二聚化抑制剂的响应
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
MX2014004021A (es) 2011-10-14 2014-04-30 Genentech Inc Usos y articulo de fabricacion que incluye el inhibidor de la dimerizacion de her2 pertuzumab.
KR101327542B1 (ko) * 2012-03-15 2013-11-08 광주과학기술원 양자점 기반의 경쟁 면역분석법 및 다중 유세포 분석법을 이용한 시료 중 오염물질의 검출 방법
AU2012232949B2 (en) * 2012-09-28 2014-07-03 Willowtree Holdings Pty Ltd Temporary bulkhead
RU2737727C2 (ru) 2013-04-16 2020-12-02 Дженентек, Инк. Варианты пертузумаба и их аналитическая характеристика
SG11201608912VA (en) 2014-04-25 2016-11-29 Genentech Inc Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
RS65871B1 (sr) 2015-05-30 2024-09-30 Hoffmann La Roche Postupci lečenja her2-pozitivnog prethodno nelečenog metastatskog karcinoma dojke
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
US20180221481A1 (en) 2016-12-28 2018-08-09 Genentech, Inc. Treatment of advanced her2 expressing cancer
TWI729259B (zh) 2017-01-17 2021-06-01 美商建南德克公司 皮下her2 抗體調配物
CN114984206A (zh) 2017-03-02 2022-09-02 基因泰克公司 Her2阳性乳腺癌的辅助治疗
TW201902509A (zh) 2017-04-24 2019-01-16 美商建南德克公司 Erbb2/her2突變
KR20230030621A (ko) 2020-06-29 2023-03-06 제넨테크, 인크. 퍼투주맙 + 트라스투주맙 고정 용량 조합

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003024993A2 (en) * 2001-09-20 2003-03-27 Board Of Regents, The University Of Texas System Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2095818B (en) 1981-03-27 1985-10-02 Exxon Research Engineering Co Staged adsorption/resorption heat pump
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP4124480B2 (ja) * 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
IL129354A0 (en) 1996-10-18 2000-02-17 Genentech Inc Anti-ErbB2 antibodies
PT2263691E (pt) * 2002-07-15 2012-11-12 Hoffmann La Roche Tratamento de cancro com o anticorpo anti-erbb2 monoclonal humanizado recombinante 2c4 (rhumab 2c4)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003024993A2 (en) * 2001-09-20 2003-03-27 Board Of Regents, The University Of Texas System Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays

Also Published As

Publication number Publication date
EP2194380A3 (en) 2010-07-14
EP2194380A2 (en) 2010-06-09
CA2613187A1 (en) 2007-01-11
US20070009976A1 (en) 2007-01-11
AR053948A1 (es) 2007-05-23
IL188317A0 (en) 2008-04-13
TW200741203A (en) 2007-11-01
MA29730B1 (fr) 2008-09-01
EP1902315A1 (en) 2008-03-26
RU2008103608A (ru) 2009-08-20
AU2006265275A1 (en) 2007-01-11
KR20080016939A (ko) 2008-02-22
NZ564471A (en) 2010-04-30
CR9635A (es) 2008-02-20
MY157955A (en) 2016-08-30
TWI312864B (en) 2009-08-01
BRPI0612591A2 (pt) 2010-11-23
NO20076662L (no) 2008-04-03
WO2007003420A1 (en) 2007-01-11
MX2008000277A (es) 2008-03-24
ECSP088081A (es) 2008-02-20

Similar Documents

Publication Publication Date Title
JP2008545145A (ja) 対応治療抗体の有無を問わない標的抗原の検出
US7279287B2 (en) Analytical method
CN110383068A (zh) 评估患者样品中uch-l1状态的改进方法
CN102625915A (zh) 糖蛋白质的测定方法、肝病的检查方法、糖蛋白质定量用试剂及肝病病情指标糖链标记糖蛋白质
JP2011039072A (ja) 実験動物における治療抗体の検出
US20180113127A1 (en) Immunoassay method and assay reagent used in said method
US20110040544A1 (en) Systems And Methods For Treating, Diagnosing And Predicting The Response To Therapy Of Breast Cancer
JP6660932B2 (ja) Ｌ−ｆａｂｐの免疫学的測定方法及び該方法に用いられる測定試薬
EP2707720B1 (en) Diagnosis and prognosis of triple negative breast and ovarian cancer
US20220146515A1 (en) Specific antibody against human anti-mullerian hormone and application thereof
CN118515772A (zh) 抗生物素单克隆抗体及其制备方法和应用
CN101213450A (zh) 不论存在或不存在相对应的治疗用抗体而检测靶抗原
Fetsch et al. The effects of antibody clone and pretreatment method on the results of HER2 immunostaining in cytologic samples of metastatic breast cancer: A query and a review of the literature
HK1115446A (en) Detecting of a target antigen irrespective of the presenace or absence of a corresponding therapeutic antibody
WO2016118531A1 (en) Methods and kits for analysis of hmgb1 isoforms
US20250044284A1 (en) Materials and methods for enhanced detection and screening of molecules of therapeutic potential
WO2023191046A1 (ja) Ｈｒｇに対するモノクローナル抗体を用いたｈｒｇの測定方法
KR20240051109A (ko) 검정 신호 증폭을 위한 방법, 조성물 및 키트
CN119371525A (zh) 抗甲状腺球蛋白抗体、试剂盒和用途
CN120513252A (zh) 环孢菌素-吖啶酯及其制备和使用方法
CN117783526A (zh) 一种定量检测生物体液中热带念珠菌烯醇化酶的方法
Ahmed Elucidation of the Principles
KR20190073600A (ko) 예측 방법 및 상기 방법에 유용한 키트

Legal Events

Date Code Title Description
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20100617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100629

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101214

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111101